

# Outline

The Medical Technology Research Group (MTRG) at LSE Health is delighted to organise and host a summit on Risk Sharing and Managed Entry Agreements (MEAs) in February 2014. Speakers from national competent authorities on pricing, reimbursement and HTA, pharmaceutical manufacturers, international organisations, patient representative organisations and academia will debate the latest developments and will also reflect on future prospects and policy options during this one-day summit in London.

Increasingly, uncertainty identified during health technology assessment of innovative new medicines is addressed through a managed entry agreement / risk-sharing agreement between the manufacturer and the payer. Over time, there has been a proliferation of managed entry schemes focusing, among other things, on price, utilisation and outcomes. During the summit, leading experts from academia, policy-making, industry and the patient community will convey their experience with the implementation of MEAs in different settings, assess the emerging evidence on schemes such as coverage with evidence development and outcomes-based risk-sharing and reflect on policy options for the future.

Delegates can expect high-calibre speakers from several countries implementing MEAs / risk-sharing agreements. Presentations will enable delegates to learn about the latest developments in the field and gain insights on implementing MEAs from different stakeholder perspectives, including a primer on collaborative approaches to coverage decisions. Delegates will also have the opportunity to network, exchange views and perspectives and become part of the LSE academic community.

Panellists will feature representatives from the Dutch Health Care Insurance Board (CVZ), Myeloma UK, Oxford University, the Swedish Dental and Pharmaceutical Benefits Board (TLV), the Italian Medicines Agency (AIFA), the European Commission and the OECD.


Sponsored by Ernst and Young



Media partner: The Financial Times



# Provisional conference programme



08.30 – 09.00  
Registration and coffee

09.00 - 09.05  
**Welcome & introduction**  
Professor David Taylor  
(chair), University  
College London

09.05 - 09.30  
**Keynote**  
  
Introduction by David  
MacMurchy, EY  
  
*A European perspective on  
MEAs*

Alessandra Ferrario and  
Panos Kanavos, London  
School of Economics  
and Political Science

**Session 1**  
  
**Lessons from  
implementing MEAs  
– Part 1**

09.30 - 09.50  
  
*Improving rational drug use  
through monitoring  
registries*  
Paolo Siviero, AIFA, Italy

09.50 - 10.10  
  
*New developments in the  
Polish risk-sharing  
landscape*  
Jakub Adamski, Polish  
Ministry of Health

10.10 - 10.30  
  
*Progress of the risk  
sharing scheme in  
providing MS drugs cost-  
effectively*  
Jackie Palace, Oxford  
University

10.30 - 10.50  
Discussion

10.50 - 11.10  
Coffee break

**Session 2**  
  
**Lessons from  
implementing MEAs  
– Part 2**

11.10 - 11.30  
  
*The ability of coverage with  
evidence development and  
to address uncertainties  
and improve performance  
in drug use*  
Karl Arnberg, TLV,  
Sweden

11.30 - 11.50  
  
*Results from the first  
re-assessments of  
coverage with evidence  
development schemes  
(CED): Is CED the way  
forward to introduce new  
and high cost medicines?*  
Caroline van der Meijden,  
Dutch Health Care  
Insurance Board (CVZ),  
the Netherlands

11.50 - 12.10  
Discussion

12.10 - 13.10  
Lunch break

**Session 3**  
  
**Stakeholder  
perspectives on  
MEAs**

13.10 - 13.30  
  
*A manufacturer's  
perspective on MEAs and  
their ability to improve  
access to medicines*  
Christophe Carbonel,  
Novartis

13.30 - 13.50  
*Can MEAs help us move  
towards a value-based  
pricing model?*  
Valerie Paris, OECD

13.50 - 14.10  
Discussion

14.10 - 14.30  
Coffee break

14.30 - 15.00  
*Communicating value:  
The benefits of  
collaborative negotiation*  
Charles Barker,  
PrimeMover Associates  
LLC

15.00 - 15.20  
Coffee break

**Session 4**  
  
**The value of  
collecting additional  
evidence to improve  
decision-making –  
current reflections  
and future options**

15.20 - 16.45  
**Panel**

**Chair:**  
Panos Kanavos

**Panellists:**  
  
Karl Arnberg, TLV,  
Sweden  
  
Salvatore D'Acunto, EU  
Commission  
  
Ansgar Hebborn, Roche  
  
Caroline van der Meijden,  
CVZ, the Netherlands  
  
Jean Mossman, European  
Brain Council

Silvia Ondategui-Parra, EY

Valerie Paris, OECD

Paolo Siviero, AIFA, Italy

Andrew Stainthorpe, NICE

16.45 - 17.00  
**Conclusions and  
farewell**  
Panos Kanavos and  
David Taylor